{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Use+of+insulin+glargine+once+daily", "query": { "intervention": "Use of insulin glargine once daily" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Use+of+insulin+glargine+once+daily&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-07T20:40:03.148Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00909480", "title": "Effect of Insulin Detemir and Insulin Glargine on Blood Glucose Control in Subjects With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin detemir", "type": "DRUG" }, { "name": "insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 457, "start_date": "2009-05", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2017-03-10", "last_synced_at": "2026-10-07T20:40:03.148Z", "location_count": 71, "location_summary": "Litchfield Park, Arizona • Searcy, Arkansas • Anaheim, California + 63 more", "locations": [ { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Searcy", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00909480" }, { "nct_id": "NCT01524705", "title": "FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Insulin Glargine", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Prandial insulin", "type": "DRUG" }, { "name": "Exenatide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 102, "start_date": "2012-08", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2023-12-29", "last_synced_at": "2026-10-07T20:40:03.148Z", "location_count": 12, "location_summary": "San Diego, California • Miami, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01524705" }, { "nct_id": "NCT01925989", "title": "A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "LY2605541", "type": "BIOLOGICAL" }, { "name": "Insulin Glargine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 27, "start_date": "2013-11", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2019-03-01", "last_synced_at": "2026-10-07T20:40:03.148Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01925989" }, { "nct_id": "NCT04760626", "title": "A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin icodec", "type": "DRUG" }, { "name": "Insulin Glargine 100U/mL", "type": "DRUG" }, { "name": "Insulin Degludec", "type": "DRUG" }, { "name": "Insulin Glargine 300U/mL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1085, "start_date": "2021-03-01", "completion_date": "2022-08-29", "has_results": true, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-07T20:40:03.148Z", "location_count": 142, "location_summary": "Birmingham, Alabama • Guntersville, Alabama • Gilbert, Arizona + 122 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Guntersville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04760626" }, { "nct_id": "NCT02365233", "title": "Fatty Liver Study in Patients With Type II Diabetes", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type II Diabetes", "Nonalcoholic Fatty Liver" ], "interventions": [ { "name": "DPP4 inhibitor", "type": "DRUG" }, { "name": "Pioglitazone", "type": "DRUG" }, { "name": "Lantus insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Medical Branch, Galveston", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2013-05-01", "completion_date": "2016-12-31", "has_results": true, "last_update_posted_date": "2018-07-31", "last_synced_at": "2026-10-07T20:40:03.148Z", "location_count": 1, "location_summary": "Galveston, Texas", "locations": [ { "city": "Galveston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02365233" }, { "nct_id": "NCT02451137", "title": "A \"Real World\" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin glargine, 300 U/ml", "type": "DRUG" }, { "name": "Insulin glargine, 100 U/ml", "type": "DRUG" }, { "name": "Insulin detemir", "type": "DRUG" }, { "name": "Background Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3304, "start_date": "2015-06-16", "completion_date": "2018-08-09", "has_results": true, "last_update_posted_date": "2019-09-10", "last_synced_at": "2026-10-07T20:40:03.148Z", "location_count": 407, "location_summary": "Birmingham, Alabama • Gulf Shores, Alabama • Guntersville, Alabama + 304 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Guntersville", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02451137" }, { "nct_id": "NCT03214380", "title": "A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "LY900014", "type": "DRUG" }, { "name": "Insulin Lispro", "type": "DRUG" }, { "name": "Insulin Glargine", "type": "DRUG" }, { "name": "Insulin Degludec", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "SGLT2 inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 933, "start_date": "2017-07-14", "completion_date": "2019-03-13", "has_results": true, "last_update_posted_date": "2020-03-27", "last_synced_at": "2026-10-07T20:40:03.148Z", "location_count": 32, "location_summary": "Fresno, California • La Mesa, California • Lancaster, California + 26 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Clarita", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03214380" }, { "nct_id": "NCT01582451", "title": "A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "LY2605541", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 466, "start_date": "2012-05", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2018-04-20", "last_synced_at": "2026-10-07T20:40:03.148Z", "location_count": 33, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Concord, California + 30 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01582451" }, { "nct_id": "NCT00732524", "title": "Combination of Sulfonylureas and Insulin Glargine Outpatient Therapy for Unstable Diabetes and Impending DKA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Glipizide", "type": "DRUG" }, { "name": "Glipizide and Glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cook County Health", "sponsor_class": "OTHER_GOV", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 80, "start_date": "2004-09", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2008-08-12", "last_synced_at": "2026-10-07T20:40:03.148Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00732524" }, { "nct_id": "NCT02741687", "title": "Sitagliptin in Non-Diabetic Patients Undergoing General Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hyperglycemia" ], "interventions": [ { "name": "Sitagliptin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Supplemental insulin (insulin lispro)", "type": "DRUG" }, { "name": "Supplemental insulin (insulin aspart)", "type": "DRUG" }, { "name": "Long acting basal insulin (insulin detemir)", "type": "DRUG" }, { "name": "Long acting basal insulin (insulin glargine)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 80, "start_date": "2016-06", "completion_date": "2017-04", "has_results": true, "last_update_posted_date": "2018-06-27", "last_synced_at": "2026-10-07T20:40:03.148Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02741687" } ] }